Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

Wed, 03rd Jan 2024 12:10

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

The latest Institute of Supply Management's manufacturing purchasing managers' index is released at 1500 GMT, before minutes from the Federal Reserve's latest meeting at 1900 GMT.

The FTSE 100 index was down 69.86 points, or 0.9%, at 7,651.66. The FTSE 250 was down 174.90 points, 0.9%, at 19,336.90, and the AIM All-Share was down 5.84 points, 0.8%, at 755.71.

The Cboe UK 100 was down 0.8% at 764.47, the Cboe UK 250 was down 1.0% at 16799.17, while the Cboe Small Companies was up 0.2% at 14,985.16.

In European equities, the CAC 40 in Paris slumped 1.3%, while the DAX 40 in Frankfurt was down 0.8%.

"The FTSE 100 marked its 40th birthday with a celebration more akin to a quiet pint in an empty pub than anything more befitting of a major landmark," said AJ Bell analyst Russ Mould.

"The index was flat after mixed trading in the US overnight, where tech stocks came under pressure. The so-called 'magnificent seven' accounted for a big chunk of the gains achieved by global stocks in 2023 and much will rest on their performance again in 2024."

The magnificent seven stocks refer to technology firms Amazon, Apple, Google parent Alphabet, Facebook owner Meta Platforms, Microsoft, Nvidia and Tesla.

Stocks in New York were called lower. The Dow Jones Industrial Average and the S&P 500 index were both called down 0.3%, while the Nasdaq Composite was called down 0.5%.

Sterling was quoted at USD1.2625 at midday on Wednesday, higher than USD1.2620 at the London equities close on Tuesday. The euro traded at USD1.0922, lower than USD1.0955. Against the yen, the dollar was quoted at JPY142.78, higher than JPY141.74.

"The dollar is getting more traction ahead of the FOMC minutes," Brown Brothers Harriman analysts commented.

"Last month's dovish Fed decision was a game changer for the dollar, but we believe markets are coming to realize that the US economy remains robust in Q4 and likely to remain so in 2024, which certainly wouldn't require six rate cuts from the Fed this year. That said, a sustained dollar recovery will really come down to the US data. Over the past few weeks, the readings have all come in quite firm and so we continue to believe that the current market easing expectations are dead wrong. Until these expectations shift, however, the dollar is likely to remain vulnerable."

In London, Tesco rose 1.3% and Sainsbury's added 1.0%.

The UK grocery sector had its busiest festive period since the onset of the Covid-19 pandemic four years ago, numbers from Kantar showed, while price inflation worries for consumers abated.

Kantar said grocery sales in the 12 weeks to December 24 rose 6.9% to GBP36.45 billion from GBP34.10 billion a year before. In the final four weeks of that period alone, sales totalled GBP13.7 billion.

Annual grocery price inflation in December eased to 6.7% from 9.1% in the four weeks to November 26. December's figure was the tamest level since April 2022, and Kantar said it was the sharpest monthly slowdown it has ever recorded.

"While inflation is coming down, prices are still rising on average albeit at a slower pace, meaning that customers are still having to spend more to obtain a similar number of items," said interactive investor analyst Victoria Scholar.

"The cost-of-living crisis has prompted shoppers to trade down to cheaper, unbranded products, a shift which has boosted sales of supermarkets' own-label lines."

Entain added 1.3%, after an activist investor joined the board. The sports betting and gambling operator appointed Ricky Sandler, founder of activist investor Eminence Capital to its board as a non-executive director.

Entain also agreed to appoint an additional non-executive director "mutually agreeable to Eminence and the company".

Sandler will be considered a non-independent non-executive director, and his three-year appointment is governed by a relationship agreement that limits Eminence to an 8% stake. Entain did not disclose Eminence's current holding, so it is less than 5%.

"After the departure of CEO Jette Nygaard-Andersen in December, the company needs to find some direction," said AJ Bell's Mould.

"At least last year's conclusion of a HMRC probe into a legacy business in Turkey provides the company with something of a clean slate from which to try and get earnings on an upwards trajectory."

GSK gained 1.4%, after Jefferies raised the pharmaceutical maker to 'buy' from 'hold', raising its price target to 1,900p from 1,550p.

In the FTSE 250, Wizz Air lost 3.3%, after the Budapest-based airline said it carried 5.0 million passengers in December, up 19% from 4.2 million the year prior. Capacity for the month was 22% higher at 6.0 million seats, compared to 4.9 million seats in December 2022.

Its load factor fell year-on-year, however, to 82.1% from 84.5%.

Ryanair, meanwhile, said it carried 12.5 million passengers in December, up 8.7% from 11.5 million in the corresponding month last year. Its load factor fell by one point to 91% from 92% the year before.

Ryanair added that it operated 72,500 flights in December, but noted that over 900 flights were cancelled due to the Israel-Gaza conflict.

Shares were down 4.0% in Dublin.

On AIM, C4X Discovery surged 50%, after the drug discovery company said it received a USD11.0 million milestone payment from FTSE 100-listed pharmaceutical firm AstraZeneca, following trials of the C4X respiratory disease therapy treatment.

The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November.

In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.

Intercede rose 18%, after it secured a "major" licence order worth USD1.0 million for a new, unnamed client in the US intelligence sector.

In addition to the perpetual licence order, the Lutterworth, England-based cybersecurity software firm said the client is also contracted for a separate annual subscription of USD200,000.

Intercede said this order, combined with the expected additional conversion of its existing pipeline in its fourth quarter, means that it now expects financial performance to be ahead of market expectations for the financial year ending March 31 and further underpins financial 2025.

Gold was quoted at USD2,051.09 an ounce at midday on Wednesday, lower than USD2,064.66 on Tuesday. Brent oil was trading at USD75.89 a barrel, lower than USD77.75.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.